BIRC5 and hepatocellular carcinoma: In the validation phase, GNAS, MSH2, and survivin displayed better diagnostic performances than other TAAs, while PTEN was not a good performer, which was consistent with previous verification results, and may have been caused by the reduction of PTEN expression in HCC tissue [49,50].